Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 3
1997 19
1998 21
1999 35
2000 30
2001 36
2002 31
2003 48
2004 48
2005 73
2006 73
2007 71
2008 62
2009 68
2010 63
2011 78
2012 70
2013 61
2014 73
2015 82
2016 64
2017 81
2018 69
2019 83
2020 81
2021 105
2022 90
2023 101
2024 42

Text availability

Article attribute

Article type

Publication date

Search Results

1,554 results

Results by year

Filters applied: . Clear all
Page 1
The CXCL8-CXCR1/2 pathways in cancer.
Liu Q, Li A, Tian Y, Wu JD, Liu Y, Li T, Chen Y, Han X, Wu K. Liu Q, et al. Cytokine Growth Factor Rev. 2016 Oct;31:61-71. doi: 10.1016/j.cytogfr.2016.08.002. Epub 2016 Aug 25. Cytokine Growth Factor Rev. 2016. PMID: 27578214 Free PMC article. Review.
Studies have suggested that CXCL8 and its cognate receptors, C-X-C chemokine receptor 1 (CXCR1) and C-X-C chemokine receptor 2 (CXCR2), mediate the initiation and development of various cancers including breast cancer, prostate cancer, lung cancer, colorectal carcinoma and …
Studies have suggested that CXCL8 and its cognate receptors, C-X-C chemokine receptor 1 (CXCR1) and C-X-C chemokine receptor 2 (CXCR2 …
Role of the CXCL8-CXCR1/2 Axis in Cancer and Inflammatory Diseases.
Ha H, Debnath B, Neamati N. Ha H, et al. Theranostics. 2017 Apr 7;7(6):1543-1588. doi: 10.7150/thno.15625. eCollection 2017. Theranostics. 2017. PMID: 28529637 Free PMC article. Review.
Interaction between CXCL8 secreted by select cancer cells and CXCR1/2 in the tumor microenvironment is critical for cancer progression and metastasis. ...During the past two decades, several small-molecule CXCR1/2 inhibitors, CXCL8 releasing inhibitors, and neutrali …
Interaction between CXCL8 secreted by select cancer cells and CXCR1/2 in the tumor microenvironment is critical for cancer progressio …
Therapeutic inhibition of CXCR1/2: where do we stand?
Sitaru S, Budke A, Bertini R, Sperandio M. Sitaru S, et al. Intern Emerg Med. 2023 Sep;18(6):1647-1664. doi: 10.1007/s11739-023-03309-5. Epub 2023 May 30. Intern Emerg Med. 2023. PMID: 37249756 Free PMC article. Review.
In addition, the pathogenetic involvement of neutrophils and the CXCL8-CXCR1/2 axis in cancer progression and metastasis is increasingly recognized. Consequently, therapeutic targeting of CXCR1/2 or CXCL8 has been intensively investigated in recent years using a wid …
In addition, the pathogenetic involvement of neutrophils and the CXCL8-CXCR1/2 axis in cancer progression and metastasis is increasin …
Targeting CXCR1 and CXCR2 receptors in cardiovascular diseases.
Dhayni K, Zibara K, Issa H, Kamel S, Bennis Y. Dhayni K, et al. Pharmacol Ther. 2022 Sep;237:108257. doi: 10.1016/j.pharmthera.2022.108257. Epub 2022 Jul 28. Pharmacol Ther. 2022. PMID: 35908611 Review.
CXCR1 and CXCR2 chemokine receptors, mainly activated by interleukin 8 (IL-8 or CXCL8), are expressed in a variety of cells including, leukocytes, fibroblasts, endothelial cells, and smooth muscle cells. ...CXCR1/2 inhibitors show beneficial effects in various anima …
CXCR1 and CXCR2 chemokine receptors, mainly activated by interleukin 8 (IL-8 or CXCL8), are expressed in a variety of cells including …
CXCR1: A Cancer Stem Cell Marker and Therapeutic Target in Solid Tumors.
Molczyk C, Singh RK. Molczyk C, et al. Biomedicines. 2023 Feb 16;11(2):576. doi: 10.3390/biomedicines11020576. Biomedicines. 2023. PMID: 36831112 Free PMC article. Review.
Typically, in the case of the tumor microenvironment, inflammatory pathways can be utilized by the tumor to aid in tumor progression; one such pathway is the CXCR1/2 pathway. The CXCR1 and CXCR2 receptors are intricately related, with CXCR1 binding two ligand …
Typically, in the case of the tumor microenvironment, inflammatory pathways can be utilized by the tumor to aid in tumor progression; one su …
Reduction of NETosis by targeting CXCR1/2 reduces thrombosis, lung injury, and mortality in experimental human and murine sepsis.
Alsabani M, Abrams ST, Cheng Z, Morton B, Lane S, Alosaimi S, Yu W, Wang G, Toh CH. Alsabani M, et al. Br J Anaesth. 2022 Feb;128(2):283-293. doi: 10.1016/j.bja.2021.10.039. Epub 2021 Dec 8. Br J Anaesth. 2022. PMID: 34893315 Free PMC article.
Similar results were observed after incubation of plasma from mice with neutrophils from septic non-septic mice. Circulating CXCR1/2 ligands correlated with NETosis in patients (interleukin-8; r=0.643) and mice (macrophage inflammatory protein-2; r=0.902). ...CONCLUSION: …
Similar results were observed after incubation of plasma from mice with neutrophils from septic non-septic mice. Circulating CXCR1/2 …
CXCR1 drives the pathogenesis of EAE and ARDS via boosting dendritic cells-dependent inflammation.
Zhuang W, Zhou J, Zhong L, Lv J, Zhong X, Liu G, Xie L, Wang C, Saimaier K, Han S, Shi C, Hua Q, Zhang R, Xie X, Du C. Zhuang W, et al. Cell Death Dis. 2023 Sep 14;14(9):608. doi: 10.1038/s41419-023-06126-y. Cell Death Dis. 2023. PMID: 37709757 Free PMC article.
Here we reported that compared with healthy controls, the level of CXCR1 was aberrantly increased in multiple sclerosis (MS) patients. ...We observed the same results in EAE mice with DCs-specific deletion of CXCR1 and antibody neutralization of the ligand CXCL5. Me …
Here we reported that compared with healthy controls, the level of CXCR1 was aberrantly increased in multiple sclerosis (MS) patients …
Targeting CXCR1/2: The medicinal potential as cancer immunotherapy agents, antagonists research highlights and challenges ahead.
Che J, Song R, Chen B, Dong X. Che J, et al. Eur J Med Chem. 2020 Jan 1;185:111853. doi: 10.1016/j.ejmech.2019.111853. Epub 2019 Nov 6. Eur J Med Chem. 2020. PMID: 31732253 Review.
Therefore, CXCR1/2 antagonists have aroused pharmaceutical interest in recent years. In this review, the medicinal chemistry of CXCR1/2 antagonists and their relevance in cancer immunotherapy have been summarized. ...
Therefore, CXCR1/2 antagonists have aroused pharmaceutical interest in recent years. In this review, the medicinal chemistry of CX …
Targeting CXCR1 alleviates hyperoxia-induced lung injury through promoting glutamine metabolism.
Qin H, Zhuang W, Liu X, Wu J, Li S, Wang Y, Liu X, Chen C, Zhang H. Qin H, et al. Cell Rep. 2023 Jul 25;42(7):112745. doi: 10.1016/j.celrep.2023.112745. Epub 2023 Jul 4. Cell Rep. 2023. PMID: 37405911 Free article.
We also combine transcriptome, proteome, and metabolome analysis and find that CXCR1 knockdown promotes glutamine metabolism and leads to reduced glutathione by upregulating the expression of malic enzyme 1. This preclinical evidence suggests that a conservative oxygen str …
We also combine transcriptome, proteome, and metabolome analysis and find that CXCR1 knockdown promotes glutamine metabolism and lead …
The CXCL8-CXCR1/2 Axis as a Therapeutic Target in Breast Cancer Stem-Like Cells.
Ruffini PA. Ruffini PA. Front Oncol. 2019 Feb 6;9:40. doi: 10.3389/fonc.2019.00040. eCollection 2019. Front Oncol. 2019. PMID: 30788286 Free PMC article. Review.
This mini review focuses on preclinical and clinical results obtained by interfering with chemokine receptors CXCR1 and CXCR2 in breast cancer. This strategy is currently being tested in a randomized, double blind phase 2 clinical trial....
This mini review focuses on preclinical and clinical results obtained by interfering with chemokine receptors CXCR1 and CXCR2 in brea …
1,554 results